Brokerages Set Akari Therapeutics PLC (AKTX) PT at $9.00

Akari Therapeutics PLC (NASDAQ:AKTX) has been given an average recommendation of “Hold” by the six ratings firms that are currently covering the firm, reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $9.00.

A number of equities research analysts have recently commented on AKTX shares. ValuEngine upgraded Akari Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, November 30th. Zacks Investment Research cut Akari Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Finally, B. Riley started coverage on Akari Therapeutics in a research note on Thursday. They set a “neutral” rating and a $3.00 target price on the stock.

Akari Therapeutics (NASDAQ:AKTX) opened at $2.32 on Thursday. Akari Therapeutics has a 52 week low of $2.06 and a 52 week high of $22.20.

Akari Therapeutics (NASDAQ:AKTX) last issued its quarterly earnings data on Monday, November 13th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.91. sell-side analysts expect that Akari Therapeutics will post -2.5 EPS for the current year.

A hedge fund recently raised its stake in Akari Therapeutics stock. Hikari Power Ltd lifted its holdings in shares of Akari Therapeutics PLC (NASDAQ:AKTX) by 152.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 151,334 shares of the biopharmaceutical company’s stock after purchasing an additional 91,322 shares during the period. Hikari Power Ltd owned about 1.28% of Akari Therapeutics worth $929,000 at the end of the most recent reporting period. Institutional investors own 21.05% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Brokerages Set Akari Therapeutics PLC (AKTX) PT at $9.00” was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at

About Akari Therapeutics

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.

Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply